Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab')2 fragments of an anti-carcinoembryonic antigen monoclonal antibody

A multicenter study

A. G. Siccardi, G. L. Buraggi, L. Callegaro, A. C. Colella, P. G. De Filippi, G. Galli, G. Mariani, R. Masi, R. Palumbo, P. Riva, M. Salvatore, G. A. Scassellati, K. Scheidhauer, G. L. Turco, P. Zaniol, S. Benini, G. Deleide, M. Gasparini, S. Lastoria

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

F(ab')2 fragments of anti-carcinoembryonic antigen (CEA) monoclonal antibody F023C5, determined to be more suitable than intact IgG and Fab fragments for immunoscintigraphy, were labeled with 131I or conjugated to DTPA for instant 111In-labeling, and administered i.v. (2-3 mCi/0.5 mg) to 509 patients in 11 nuclear medicine departments: 284 patients had gastrointestinal adenocarcinomas, 204 had nongastrointestinal adenocarcinomas and 21 were controls; serum CEA was elevated in 169 patients, normal in 115, and not determined in 225. The following results were obtained: (a) no adverse reactions; (b) tumor imaging in 324 patients (in particular, in 81.5% CEA-seropositive and in 69.0% CEA-seronegative patients); (c) no significant difference in sensitivity among the results of the 11 departments; (d) no significant difference in overall sensitivity between 131I- and 111In-labeled immunoradiopharmaceuticals; (e) the fraction of documented lesions imaged was 73.3% in CEA-seropositive and 53.7% in CEA-seronegative patients; (f) the detection of liver metastases was hampered, particularly when using the 111In-labeled reagent, by nonspecific radioactivity uptake; (g) the major cause of negative immunoscintigraphy results was a lack of CEA in tumor lesions, as documented by immunohistochemistry; (h) lesion size is also important since the sensitivity was 64% for lesions up to 2 cm in diameter and 84% for larger lesions; (i) many 'unexpected' radiolocalizations were recorded. Most were identified as occult tumor lesions. In 35 patients, this finding contributed to the early detection of tumor recurrence.

Original languageEnglish
Pages (from-to)3095-3103
Number of pages9
JournalCancer Research
Volume49
Issue number11
Publication statusPublished - 1989

Fingerprint

Carcinoembryonic Antigen
Multicenter Studies
Adenocarcinoma
Monoclonal Antibodies
Neoplasms
Pentetic Acid
Immunoglobulin Fab Fragments
Nuclear Medicine
Radioactivity
Immunoglobulin G
Immunohistochemistry
Neoplasm Metastasis
Recurrence
Liver
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab')2 fragments of an anti-carcinoembryonic antigen monoclonal antibody : A multicenter study. / Siccardi, A. G.; Buraggi, G. L.; Callegaro, L.; Colella, A. C.; De Filippi, P. G.; Galli, G.; Mariani, G.; Masi, R.; Palumbo, R.; Riva, P.; Salvatore, M.; Scassellati, G. A.; Scheidhauer, K.; Turco, G. L.; Zaniol, P.; Benini, S.; Deleide, G.; Gasparini, M.; Lastoria, S.

In: Cancer Research, Vol. 49, No. 11, 1989, p. 3095-3103.

Research output: Contribution to journalArticle

Siccardi, AG, Buraggi, GL, Callegaro, L, Colella, AC, De Filippi, PG, Galli, G, Mariani, G, Masi, R, Palumbo, R, Riva, P, Salvatore, M, Scassellati, GA, Scheidhauer, K, Turco, GL, Zaniol, P, Benini, S, Deleide, G, Gasparini, M & Lastoria, S 1989, 'Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab')2 fragments of an anti-carcinoembryonic antigen monoclonal antibody: A multicenter study', Cancer Research, vol. 49, no. 11, pp. 3095-3103.
Siccardi, A. G. ; Buraggi, G. L. ; Callegaro, L. ; Colella, A. C. ; De Filippi, P. G. ; Galli, G. ; Mariani, G. ; Masi, R. ; Palumbo, R. ; Riva, P. ; Salvatore, M. ; Scassellati, G. A. ; Scheidhauer, K. ; Turco, G. L. ; Zaniol, P. ; Benini, S. ; Deleide, G. ; Gasparini, M. ; Lastoria, S. / Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab')2 fragments of an anti-carcinoembryonic antigen monoclonal antibody : A multicenter study. In: Cancer Research. 1989 ; Vol. 49, No. 11. pp. 3095-3103.
@article{b75d6a4c90ba4dc2b4eef859cc740c3f,
title = "Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab')2 fragments of an anti-carcinoembryonic antigen monoclonal antibody: A multicenter study",
abstract = "F(ab')2 fragments of anti-carcinoembryonic antigen (CEA) monoclonal antibody F023C5, determined to be more suitable than intact IgG and Fab fragments for immunoscintigraphy, were labeled with 131I or conjugated to DTPA for instant 111In-labeling, and administered i.v. (2-3 mCi/0.5 mg) to 509 patients in 11 nuclear medicine departments: 284 patients had gastrointestinal adenocarcinomas, 204 had nongastrointestinal adenocarcinomas and 21 were controls; serum CEA was elevated in 169 patients, normal in 115, and not determined in 225. The following results were obtained: (a) no adverse reactions; (b) tumor imaging in 324 patients (in particular, in 81.5{\%} CEA-seropositive and in 69.0{\%} CEA-seronegative patients); (c) no significant difference in sensitivity among the results of the 11 departments; (d) no significant difference in overall sensitivity between 131I- and 111In-labeled immunoradiopharmaceuticals; (e) the fraction of documented lesions imaged was 73.3{\%} in CEA-seropositive and 53.7{\%} in CEA-seronegative patients; (f) the detection of liver metastases was hampered, particularly when using the 111In-labeled reagent, by nonspecific radioactivity uptake; (g) the major cause of negative immunoscintigraphy results was a lack of CEA in tumor lesions, as documented by immunohistochemistry; (h) lesion size is also important since the sensitivity was 64{\%} for lesions up to 2 cm in diameter and 84{\%} for larger lesions; (i) many 'unexpected' radiolocalizations were recorded. Most were identified as occult tumor lesions. In 35 patients, this finding contributed to the early detection of tumor recurrence.",
author = "Siccardi, {A. G.} and Buraggi, {G. L.} and L. Callegaro and Colella, {A. C.} and {De Filippi}, {P. G.} and G. Galli and G. Mariani and R. Masi and R. Palumbo and P. Riva and M. Salvatore and Scassellati, {G. A.} and K. Scheidhauer and Turco, {G. L.} and P. Zaniol and S. Benini and G. Deleide and M. Gasparini and S. Lastoria",
year = "1989",
language = "English",
volume = "49",
pages = "3095--3103",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab')2 fragments of an anti-carcinoembryonic antigen monoclonal antibody

T2 - A multicenter study

AU - Siccardi, A. G.

AU - Buraggi, G. L.

AU - Callegaro, L.

AU - Colella, A. C.

AU - De Filippi, P. G.

AU - Galli, G.

AU - Mariani, G.

AU - Masi, R.

AU - Palumbo, R.

AU - Riva, P.

AU - Salvatore, M.

AU - Scassellati, G. A.

AU - Scheidhauer, K.

AU - Turco, G. L.

AU - Zaniol, P.

AU - Benini, S.

AU - Deleide, G.

AU - Gasparini, M.

AU - Lastoria, S.

PY - 1989

Y1 - 1989

N2 - F(ab')2 fragments of anti-carcinoembryonic antigen (CEA) monoclonal antibody F023C5, determined to be more suitable than intact IgG and Fab fragments for immunoscintigraphy, were labeled with 131I or conjugated to DTPA for instant 111In-labeling, and administered i.v. (2-3 mCi/0.5 mg) to 509 patients in 11 nuclear medicine departments: 284 patients had gastrointestinal adenocarcinomas, 204 had nongastrointestinal adenocarcinomas and 21 were controls; serum CEA was elevated in 169 patients, normal in 115, and not determined in 225. The following results were obtained: (a) no adverse reactions; (b) tumor imaging in 324 patients (in particular, in 81.5% CEA-seropositive and in 69.0% CEA-seronegative patients); (c) no significant difference in sensitivity among the results of the 11 departments; (d) no significant difference in overall sensitivity between 131I- and 111In-labeled immunoradiopharmaceuticals; (e) the fraction of documented lesions imaged was 73.3% in CEA-seropositive and 53.7% in CEA-seronegative patients; (f) the detection of liver metastases was hampered, particularly when using the 111In-labeled reagent, by nonspecific radioactivity uptake; (g) the major cause of negative immunoscintigraphy results was a lack of CEA in tumor lesions, as documented by immunohistochemistry; (h) lesion size is also important since the sensitivity was 64% for lesions up to 2 cm in diameter and 84% for larger lesions; (i) many 'unexpected' radiolocalizations were recorded. Most were identified as occult tumor lesions. In 35 patients, this finding contributed to the early detection of tumor recurrence.

AB - F(ab')2 fragments of anti-carcinoembryonic antigen (CEA) monoclonal antibody F023C5, determined to be more suitable than intact IgG and Fab fragments for immunoscintigraphy, were labeled with 131I or conjugated to DTPA for instant 111In-labeling, and administered i.v. (2-3 mCi/0.5 mg) to 509 patients in 11 nuclear medicine departments: 284 patients had gastrointestinal adenocarcinomas, 204 had nongastrointestinal adenocarcinomas and 21 were controls; serum CEA was elevated in 169 patients, normal in 115, and not determined in 225. The following results were obtained: (a) no adverse reactions; (b) tumor imaging in 324 patients (in particular, in 81.5% CEA-seropositive and in 69.0% CEA-seronegative patients); (c) no significant difference in sensitivity among the results of the 11 departments; (d) no significant difference in overall sensitivity between 131I- and 111In-labeled immunoradiopharmaceuticals; (e) the fraction of documented lesions imaged was 73.3% in CEA-seropositive and 53.7% in CEA-seronegative patients; (f) the detection of liver metastases was hampered, particularly when using the 111In-labeled reagent, by nonspecific radioactivity uptake; (g) the major cause of negative immunoscintigraphy results was a lack of CEA in tumor lesions, as documented by immunohistochemistry; (h) lesion size is also important since the sensitivity was 64% for lesions up to 2 cm in diameter and 84% for larger lesions; (i) many 'unexpected' radiolocalizations were recorded. Most were identified as occult tumor lesions. In 35 patients, this finding contributed to the early detection of tumor recurrence.

UR - http://www.scopus.com/inward/record.url?scp=0024320366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024320366&partnerID=8YFLogxK

M3 - Article

VL - 49

SP - 3095

EP - 3103

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 11

ER -